High-risk combined screen: Next steps – NIPT or diagnostic test

Quick take: A high‑risk combined first‑trimester screen means the chance of a chromosomal condition—most often Down syndrome—is higher than the typical low‑risk threshold. The next step is usually a choice between a non‑invasive prenatal test (NIPT) or an invasive diagnostic procedure such as amniocentesis or chorionic villus sampling (CVS). NIPT offers very high accuracy with virtually no miscarriage risk, while invasive tests give a definitive diagnosis but carry a small procedural risk.

It’s 2 a.m., you’ve just finished a restless night of nausea, and the result on your phone reads “high‑risk combined screen.” Your heart races, and a cascade of questions floods your mind: “Is my baby okay? Do I need another test? How long will I have to wait?” You’re not alone—many expectant parents feel the same mix of anxiety and urgency after a high‑risk screen.

First, breathe. A high‑risk result is a statistical flag, not a diagnosis. It tells you that, based on your blood markers, nuchal translucency measurement, and maternal age, the probability of a chromosomal abnormality is higher than the standard cutoff (often 1 in 250). The good news is that you have clear, evidence‑based pathways to follow, each with its own benefits, limitations, and timelines.

In this guide we’ll walk through what the combined screen looks at, compare the two main follow‑up options—NIPT and invasive diagnostic testing—and help you weigh factors like gestational age, personal comfort, cost, and insurance. By the end you’ll have a roadmap for the conversation you’ll have with your provider, and you’ll know exactly what questions to ask.

What the combined first‑trimester screen measures and what “high‑risk” means

The combined first‑trimester screen (sometimes called the “combined test”) is typically performed between 11 and 13 weeks + 6 days. It blends three pieces of information:

• Maternal serum markers: Levels of pregnancy‑associated plasma protein‑A (PAPP‑A) and free beta‑human chorionic gonadotropin (β‑hCG).
• Nuchal translucency (NT) ultrasound: The thickness of the fluid‑filled space at the back of the fetus’s neck.
• Maternal age and sometimes weight: Age is a strong predictor of chromosomal risk.

These data are entered into an algorithm that outputs a risk estimate for the most common aneuploidies—trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). In most U.S. and U.K. guidelines a result of 1 in 250 or greater for trisomy 21 is labeled “high‑risk.” A high‑risk screen does not mean your baby definitely has a chromosomal condition; it means the probability is higher than the baseline risk for the general pregnant population.

Because the combined screen is a screening tool, not a diagnostic test, the next step is always a confirmatory or clarifying test. This is where the choice between NIPT and invasive diagnostics enters the picture. The algorithm’s risk number is only as reliable as the quality of the ultrasound and the timing of the blood draw, so a repeat or confirmatory test can often refine the estimate further before moving to more invasive options.

Non‑invasive prenatal testing (NIPT): how it works, accuracy, and timing

NIPT

Because NIPT looks directly at genetic material, its analytical sensitivity is high. Large‑scale studies cited by the American College of Obstetricians and Gynecologists (ACOG) report detection rates of > 99 % for trisomy 21, > 97 % for trisomy 18, and > 95 % for trisomy 13, with false‑positive rates under 0.5 % for most conditions. In other words, a positive NIPT result is highly suggestive, but still a screen—confirmatory invasive testing is recommended before any definitive clinical decision.

Timing is flexible. While the test can be ordered as early as 9 weeks, many providers wait until after the combined screen (around 11–13 weeks) to use the high‑risk result as a trigger for NIPT. Results typically return within 7–10 days, though some labs promise a 5‑day turnaround for expedited orders. This rapid timeline can be a relief compared with the longer waiting periods for invasive diagnostics.

Because NIPT requires only a blood draw, there’s essentially no miscarriage risk. The procedure is safe for all pregnancies, regardless of maternal age or prior obstetric history. However, the test does not detect all genetic conditions—structural chromosome abnormalities, microdeletions, or single‑gene disorders may be missed unless a specialized panel is ordered. For families with a known familial mutation, a targeted NIPT panel can sometimes be added, but it still does not replace diagnostic testing when a definitive answer is required.

Invasive diagnostic testing: amniocentesis and chorionic villus sampling (CVS)

When a definitive diagnosis is needed—especially before major decisions or when a pregnancy is already at higher gestational age—amniocentesis or CVS are the gold‑standard options. Both involve inserting a fine needle through the abdomen into the uterus under ultrasound guidance, but they differ in timing and the tissue sampled.

Amniocentesis

• When: Typically performed between 15 and 20 weeks + 6 days.
• What’s collected: A small amount of amniotic fluid, which contains fetal cells.
• Procedure: A 20‑gauge needle is inserted through the uterine wall; the sample is sent for karyotyping, microarray, or sequencing.
• Risks: Procedure‑related miscarriage risk is estimated at 0.1‑0.3 % (1 in 1,000 to 1 in 300). Minor complications include cramping, spotting, or infection (≈ 0.5 %).
• Result time: Conventional karyotype results take 10–14 days; rapid aneuploidy testing can be as quick as 5 days.

Chorionic villus sampling (CVS)

• When: Performed earlier, between 10 and 13 weeks + 6 days, making it the quickest way to obtain a definitive diagnosis.
• What’s collected: Small pieces of placental tissue (villi) that share the fetus’s genetic makeup.
• Procedure: Either transcervical (through the cervix) or transabdominal (through the abdomen) needle insertion under ultrasound guidance.
• Risks: Slightly higher miscarriage risk than amniocentesis—about 0.5‑1 % (1 in 200 to 1 in 100). Also a small risk of limb‑body wall defects if performed before 10 weeks, which is why most providers wait until after 10 weeks.
• Result time: Similar to amniocentesis—karyotype 10–14 days; rapid tests 5–7 days.

Both procedures provide a diagnostic answer: the chromosome count is directly observed, so false‑positive and false‑negative rates are essentially zero, assuming a technically successful sample. Modern labs can also perform chromosomal microarray analysis (CMA) on the same sample, which detects sub‑microscopic deletions and duplications that standard karyotyping would miss.

Comparing NIPT and diagnostic testing

The decision often comes down to three core dimensions: how accurately each test detects the condition you’re concerned about, how safe the test is, and how long you’ll wait for results.

In short, NIPT offers a very high detection rate with virtually no procedural risk, but it remains a screen. Invasive testing provides a definitive answer at the cost of a small miscarriage risk and a later timing window (for amniocentesis) or a slightly earlier but still invasive window (for CVS). The choice often hinges on how quickly you need certainty and how comfortable you feel with the small procedural risk.

Deciding which route fits you: gestational age, risk tolerance, medical history, and personal preferences

Every pregnancy is unique, and the “right” next step is a personal decision. Below are the most common factors that shape the conversation with your provider.

• Gestational age: If you’re still under 13 weeks, CVS is an option, but many clinicians prefer NIPT first because it avoids an invasive procedure while still giving an answer early enough to plan further testing if needed.
• Risk tolerance: Some parents are comfortable with a 0.2 % procedural risk for a definitive result; others would rather avoid any invasive step unless absolutely necessary. Your feelings about miscarriage risk are valid and should guide the discussion.
• Medical history: Prior miscarriage, uterine anomalies, or a family history of chromosomal disorders may influence which test is safest or preferred.
• Personal timeline: If you need a result before a certain milestone—such as a planned surgery, a work‑related deadline, or a prenatal screening schedule—NIPT’s quick turnaround can be decisive.
• Depth of information desired: Invasive testing can also detect structural chromosome abnormalities (e.g., balanced translocations) and, if a microarray is ordered, sub‑microscopic deletions that NIPT panels may miss.

Putting these pieces together often looks like this: you receive a high‑risk combined screen, you discuss the result with your obstetrician, and you decide whether to proceed directly to an invasive test (if you need a definitive answer now) or to start with NIPT (if you prefer a low‑risk, quick screen before committing to an invasive procedure).

For those who want to see how their own numbers stack up, you can calculate a personalized risk using the First‑Trimester Combined Screen calculator. This tool lets you input your serum marker levels, nuchal translucency measurement, and maternal age to get a clear picture of where you fall on the risk spectrum.

Cost, insurance coverage, and logistical considerations

Financial factors often influence the decision as much as medical ones. Here’s a quick snapshot of typical costs in the United States and United Kingdom, noting that prices vary by provider and region.

• NIPT: U.S. private‑pay price ranges from $800 to $2,100 per test; many insurance plans cover it when a high‑risk screen is present. In the U.K., the NHS offers NIPT for high‑risk pregnancies at no out‑of‑pocket cost, though some private labs charge £600–£900.
• Amniocentesis: About $1,500–$3,000 in the U.S., often covered by insurance when medically indicated. In the U.K., NHS coverage is standard for high‑risk cases, with private options costing £800–£1,200.
• CVS: Similar to amniocentesis in cost, though some clinics charge a premium for the earlier timing.

Insurance coverage can be nuanced. Some U.S. plans require pre‑authorization or a documented high‑risk screening result before approving NIPT, while others may consider the test investigational for low‑risk pregnancies. In the U.K., NHS eligibility criteria are usually based on a risk threshold of 1 in 150 for trisomy 21, but private insurers may have different thresholds.

Logistics matter, too. NIPT is done in a single blood draw, often in a primary‑care office. Amniocentesis and CVS require a scheduled appointment at a hospital or specialized clinic, an ultrasound for guidance, and a post‑procedure monitoring period (usually 30 minutes to a few hours). Travel distance, time off work, and childcare for older siblings can affect which option feels most feasible.

Planning your next steps: counseling, informed consent, and coordination with your care team

After a high‑risk combined screen, the most important next move is a thorough counseling session with a qualified provider—usually your obstetrician, a maternal‑fetal medicine (MFM) specialist, or a genetic counselor. The goals of that discussion are:

1. Clarify the result: Explain what the risk number means, what conditions are being screened for, and the limitations of the screen.
2. Explore options: Review NIPT, amniocentesis, and CVS, including the benefits, risks, and timing of each.
3. Address values: Ask about your comfort with procedural risk, desire for definitive answers, and any cultural or personal considerations.
4. Obtain informed consent: For any invasive test, a signed consent form outlines the procedure, risks, and alternatives. For NIPT, consent is generally a brief verbal acknowledgment, but documentation of the discussion is still recommended.
5. Set a timeline: Determine when you’ll schedule the chosen test, when results are expected, and how they fit into your overall prenatal care schedule.

Documentation matters. Your provider should give you a written summary of the discussion, including the risk estimate, the chosen next‑step test, and any follow‑up appointments. This transparency helps you feel in control and provides a reference for later decisions.

Finally, remember that you can combine approaches. Some families opt for NIPT first; if it’s positive, they then proceed to amniocentesis or CVS for confirmation. Others, especially those who need a definitive answer quickly (e.g., prior to a scheduled fetal surgery), may go straight to CVS. The pathway is flexible, and the best choice aligns with your medical needs and personal preferences.

From our medical team: A high‑risk combined screen is a signal, not a sentence. NIPT offers a safe, fast, and highly accurate way to refine that signal, while invasive testing provides the only definitive diagnosis. Take the time to discuss both options with a trusted provider, consider your own comfort with risk, and remember that you’re not alone—many families face the same crossroads and find a path that feels right for them.

Understanding false‑positive and false‑negative results

A “false‑positive” means the screening test suggests a chromosomal abnormality when none exists. With NIPT, false‑positive rates for trisomy 21 are under 0.5 % according to ACOG‑endorsed data, but they can be slightly higher for rarer conditions. A false‑positive can cause unnecessary anxiety, which is why confirmatory invasive testing is recommended before any irreversible decisions.

A “false‑negative” occurs when a test misses an existing abnormality. NIPT’s false‑negative rate for trisomy 21 is about 0.1‑0.3 %, meaning the test is extremely sensitive but not infallible. Factors that can increase false‑negative risk include low fetal fraction (the proportion of fetal cfDNA in maternal blood) and maternal obesity. If the fetal fraction is low, labs may issue a “no‑call” result, prompting a repeat draw or direct referral to diagnostic testing.

Emotional support and counseling resources

Receiving a high‑risk result can feel isolating, but there are resources to help you process the news. Many hospitals have on‑site genetic counselors who specialize in delivering results with empathy and can guide you through decision‑making. Support groups—both in‑person and online—offer a space to hear from other parents who have walked the same path. Organizations such as the Down Syndrome Association (UK) or the National Down Syndrome Society (US) provide educational materials, webinars, and peer‑mentor programs.

It’s also helpful to involve your partner, family, or trusted friend in counseling appointments. Sharing the information reduces the emotional burden and ensures that everyone who may be part of the decision‑making process has accurate facts. If anxiety or depression becomes overwhelming, consider speaking with a mental‑health professional who has experience in perinatal care.

Future options: prenatal whole‑genome sequencing and research studies

Beyond standard NIPT panels, some laboratories are offering prenatal whole‑genome sequencing (WGS) as part of research protocols. WGS can identify a broader range of genetic variants, including rare single‑gene disorders, but it also raises ethical considerations around incidental findings and data interpretation. The FDA currently classifies these expanded tests as investigational, and they are generally only available through clinical trials or specialized centers.

If you’re interested in participating in a research study, ask your provider about ongoing trials at academic medical centers. Participation can give you early access to cutting‑edge testing while contributing valuable data to improve future prenatal care. However, always weigh the potential benefits against the uncertainty and the need for thorough counseling about what the results could mean for you and your family.

Myth vs. fact

Myth: A high‑risk combined screen means your baby definitely has Down syndrome.

Fact: The screen indicates an elevated probability; most babies with a high‑risk result are still chromosomally normal. Follow‑up testing is needed to confirm.

Myth: NIPT can replace amniocentesis or CVS completely.

Fact: NIPT is a screening test. It cannot detect all chromosomal abnormalities or structural issues, so a diagnostic test is still recommended if a definitive answer is required.

Myth: Invasive tests always cause miscarriage.

Fact: The risk of miscarriage after amniocentesis is about 0.1‑0.3 %; after CVS, it’s about 0.5‑1 %. The majority of procedures are completed without any complication.

Key takeaways

• High‑risk combined screen results are statistical alerts; they don’t diagnose a condition.
• NIPT offers >99 % detection for trisomy 21 with virtually no procedural risk and results in about a week.
• Amniocentesis and CVS provide a definitive diagnosis but carry a small miscarriage risk (0.1‑1 %).
• Choose NIPT first if you prefer a low‑risk, quick answer; choose invasive testing if you need certainty before a specific medical decision.
• Insurance often covers NIPT when a high‑risk screen is present; check your plan’s pre‑authorization requirements.
• Schedule a counseling session with your OB‑GYN, MFM specialist, or genetic counselor to weigh risks, benefits, and personal values before deciding.
• Remember that false‑positive and false‑negative results can happen; confirmatory testing is the gold standard for certainty.

Frequently asked questions

What does a high‑risk combined screen result mean?

A high‑risk result means the calculated chance of a chromosomal abnormality (most often trisomy 21) exceeds the standard low‑risk threshold (commonly 1 in 250). It is a screening outcome, not a diagnosis, and should be followed by a more definitive test such as NIPT or invasive diagnostics.

Is NIPT accurate enough to replace invasive diagnostic testing?

NIPT is highly accurate for the most common aneuploidies—detecting >99 % of trisomy 21 cases with a false‑positive rate under 0.5 %—but it remains a screen. If NIPT is positive, most providers still recommend amniocentesis or CVS for confirmation before any major clinical decision.

When should I consider amniocentesis after a high‑risk screen?

Amniocentesis is typically considered after a high‑risk combined screen if you want a definitive diagnosis and are comfortable with a small procedural risk, or if NIPT is unavailable, declined, or yields a positive result that you wish to confirm.

What are the risks of NIPT compared to amniocentesis or CVS?

NIPT carries essentially no procedural risk because it uses a simple maternal blood draw. Amniocentesis has a miscarriage risk of about 0.1‑0.3 %, while CVS carries a slightly higher risk of 0.5‑1 % and a rare risk of limb‑body‑wall defects if performed before 10 weeks.

How long does it take to get NIPT results after a high‑risk screen?

Most laboratories deliver NIPT results within 5‑10 days after the blood sample is received. Some providers offer expedited processing for an additional fee, delivering results in as few as 3 days.

Can I have both NIPT and diagnostic testing, and why would I do that?

Yes. Many patients start with NIPT because it’s low‑risk and quick; if NIPT returns a positive result, they then proceed to amniocentesis or CVS for a definitive diagnosis. This staged approach balances safety with certainty.

What should I do if my NIPT result is “no‑call” or inconclusive?

A “no‑call” often means the fetal fraction of cfDNA was too low for reliable analysis, which can happen with higher maternal BMI or early gestational age. Your provider will usually recommend repeating the blood draw in a week or moving directly to diagnostic testing, especially if the original combined screen was high‑risk.

Are there any lifestyle changes that can affect the accuracy of NIPT?

Unlike invasive tests, NIPT accuracy is not influenced by maternal diet, supplements, or activity level. However, smoking and obesity can lower the fetal fraction, potentially leading to a no‑call result. Maintaining a healthy weight and avoiding tobacco can improve the chances of a successful NIPT.

When to call your doctor

If you experience any of the following after a blood draw or invasive procedure, contact your obstetrician or midwife immediately: heavy vaginal bleeding, sudden abdominal pain, fever greater than 100.4 °F (38 °C), foul‑smelling discharge, or feeling faint or dizzy. This article is for informational purposes only and does not replace personalized medical advice.

References

1. American College of Obstetricians and Gynecologists (ACOG). “Noninvasive Prenatal Testing for Fetal Aneuploidy.” Practice Bulletin, 2023.
2. National Institute for Health and Care Excellence (NICE). “Prenatal screening and diagnosis of fetal anomalies.” Clinical guideline CG62, 2022.
3. Society for Maternal‑Fetal Medicine (SMFM). “Guidelines for invasive prenatal testing.” Committee opinion, 2021.
4. U.S. Food and Drug Administration (FDA). “Cell‑free DNA testing for fetal aneuploidy.” Guidance documents, 2022.
5. World Health Organization (WHO). “Maternal and newborn health: antenatal care guidelines.” 2021.
6. Royal College of Obstetricians and Gynaecologists (RCOG). “Prenatal screening for chromosomal abnormalities.” Green‑top guideline, 2022.
7. National Health Service (NHS). “Non‑invasive prenatal testing (NIPT).” Patient information, 2023.
8. Centers for Disease Control and Prevention (CDC). “Prenatal Screening and Diagnosis.” 2022.
9. Mayo Clinic. “Amniocentesis.” Patient care information, 2023.
10. Fetal Medicine Foundation. “Chorionic villus sampling (CVS) – Risks and benefits.” 2022.
11. Down Syndrome Association (UK). “Understanding screening and diagnostic testing.” 2023.
12. National Down Syndrome Society (US). “Genetic counseling and support resources.” 2023.